INVESTOR RELATIONS

2018 News

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
02/13/18Nantkwest and Frankfurt University Hospital Announce First in Human Dosing of off-the-Shelf HER2.taNK (Car–natural Killer) Cell Therapy in Glioblastoma
CULVER CITY, Calif.--(BUSINESS WIRE)--Feb. 13, 2018-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, today announced that the first patient has been dosed in a first-in-human, Phase I clinical study in glioblastoma of HER2.taNK, a novel, natural killer cell-based immuno-oncology therapy using... 
Printer Friendly Version
01/11/18Dr. Patrick Soon-Shiong Presents at the 36th Annual J.P. Morgan Healthcare Conference
Download Presentation (PDF)To watch the WebcastTo Listen to the Webcast... 
Printer Friendly Version
01/05/18Nantworks To Present Healthcare And Biotechnology Platforms At 36th Annual J.P. Morgan Healthcare Conference On January 9, 2018 In San Francisco, CA
Announces a Record 25 Letters of Authorization to Proceed with Clinical Trials Covering 12 Novel Biological Molecules in 20 Tumor Types January 5, 2018 — Culver City, California — NantWorks, the parent organization of NantHealth (NASDAQ: NH) and NantKwest (NASDAQ: NK) announced today that Dr. Patrick Soon-Shiong (Chairman, CEO, and Founder) will present the current status of these companies and the overall ecosystem of NantWorks. Specific details will be presented regarding the current status of... 
Printer Friendly Version
01/05/18NantKwest to Host 3rd Annual Investor/Analyst Day Highlighting a Record Number of 15 INDs Authorized in 2017 Covering 12 Tumor Types with First In-Human Clinical Data of Safety and Early Signs of Clinical Activity of the NANT Cancer Vaccine
CULVER CITY, Calif.--(BUSINESS WIRE)--Jan. 5, 2018-- NantKwest (NASDAQ: NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of the human immune system using natural killer (NK) cells to treat cancer, announced today that the company will be hosting an Investor/Analyst Day on Tuesday, January 9th in San Francisco, California. NantKwest will be sharing with analysts and investors a review ... 
Printer Friendly Version